Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook.

ABSTRACT: Immunotherapy (IO) has revolutionized the therapy landscape of non-small cell lung cancer (NSCLC), significantly prolonging the overall survival (OS) of advanced stage patients. Over the recent years IO therapy has been broadly integrated into the first-line setting of non-oncogene driven NSCLC, either in combination with chemotherapy, or in selected patients with PD-L1^high expression as monotherapy. Still, a significant proportion of patients suffer from disease progression. A better understanding of resistance mechanisms depicts a central goal to avoid or overcome IO resistance and to improve patient outcome.We here review major cellular and molecular pathways within the tumor microenvironment (TME) that may impact the evolution of IO resistance. We summarize upcoming treatmen

SUBMITTER: Horvath L 

PROVIDER: S-EPMC7488475 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature